FDA Approves Synjardy for Type 2 Diabetes
Boehringer Ingelheim and Eli Lilly announced in a news release that the US Food and Drug Administration has granted approval for a new, SGLT2 inhibitor/metformin combination drug called Synjardy for people with type 2 diabetes.
-
Sell Your Test Strips for Cash
Sell Your Test Strips With Confidence. We Offer Top Prices, Free Shipping, Fast Payments.
www.assistdiabetics.com
See It Now -
We Buy Your Unused Test Strips
Do You Have Unused Diabetes Test Strips? Get Cash Fast For Your Test Strips. Earn Money Today.
www.assistdiabetics.com/sell/test/strips
See It Now
Synjardy combines the sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin with metformin hydrochloride.
It becomes the third approved drug in the United States that contains empagliflozin -- the others being Glyxambi and Jardiance -- and it is also the third SGLT2 inhibitor/metformin combination to arrive on the US market, preceded by Xigduo XR and Invokamet.
Synjardy was approved for the European market in May 2015.
The FDA has approved Synjardy as an adjunct or addition to diet and exercise in efforts to improve glycemic control in adults with type 2 diabetes who are not adequately controlled with either empagliflozin or metformin as therapies unto themselves (monotherapies), or in patients already being treated with either empagliflozin and metformin.
Synjardy is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.
The FDA will include on Synjardy a boxed warning, as it includes with all products containing metformin, which warns about the risk of lactic acidosis.
Source: Lilly
Get a Free Diabetes Meal Plan
Get a free 7-Day Diabetes Meal Plan from Constance Brown-Riggs who is a Registered Dietitian-Certified Diabetes Educator and who is also a national spokesperson for the American Dietetic Association.
Just enter in your email below to download your free Diabetes Meal Plan.